BioSpace News Archive

Synthetic biology company taking major steps in worldwide effort to put a stop to the SARS-CoV-2 outbreak, including co-funding purchases of BioXp™ 3200 System.

Medexus Pharmaceuticals Inc. provided a business update and announced its financial and operating results for the three- and nine- month periods ended December 31, 2019. All dollar amounts below are in Canadian dollars.

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding Merck’s supplemental Biologics License Applications seeking to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include a 400 mg dose infused over 30 minutes every-six-weeks option in multiple indications.

Gilead Sciences, Inc. announced that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2 at 12:00 p.m. Eastern Time.

Vanda Pharmaceuticals Inc. announced it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market closes.

Combining Leading Genetics Library With Proprietary, Commercial Scale Propagation Technology Sets Stage for Fundamental Changes in Hemp and Cannabis Markets

Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery.